• Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
Search
Medicines Law & Policy Research and resources on intellectual property and health
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About

Christopher Garrison

7 POSTS 0 COMMENTS

Lessons for a pandemic preparedness treaty from previous successes and failures with treaty-based technology...

Christopher Garrison - October 19, 2021

We need a Global Vaccines Taskforce, not just a British or European one

Christopher Garrison - February 24, 2021

What is the ‘know-how gap’ problem and how might it impact scaling up production...

Christopher Garrison - December 16, 2020

How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine

Christopher Garrison - October 5, 2020

Price, profit and the Covid-19 health technology pool: The example of remdesivir

Christopher Garrison - May 28, 2020

Never say never – Why the High Income Countries that opted-out from the Art....

Christopher Garrison - April 8, 2020

Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...

Christopher Garrison - March 30, 2020
Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
 This work is licensed under Creative Commons.